| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Net income | -24.0 | -8.2 |
| EPS (diluted, $ a share) | $-8.51 | $-14.58 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: SPRB. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Spruce Biosciences, Inc.: key numbers
- Share price
- $42.25Close, Nov 16
- Market cap
- $121M
- Shares outstanding
- 2.87MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Spruce Biosciences, Inc.
All →Spruce Biosciences Financial Results
Spruce Biosciences reported Q3 2026 financial results and confirmed it remains on track to submit a Biologics License Application (BLA) for TA-ERT in December 2026. The company also amended its loan agreement with Avenue Capital to increase tranche availability to $15 million and announced the separation of its CRHX-101 program into a new entity, Adrenyx Biosciences.
- Term
- Q3 2026
“We are executing with discipline as we complete the final steps toward our planned BLA submission for TA-ERT in December, which we believe will be a defining milestone for Spruce and for the children and families living with MPS IIIB.”
Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer of Spruce Biosciences
“Our amended Avenue Loan Agreement expands our near-term access to debt capital and extends our interest-only period, giving us added financial flexibility as we move through BLA review and prepare for a potential U.S. commercial launch.”
Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer of Spruce Biosciences